Meet Thoracic Surgeon James Huang
James Huang, MD
Thymoma and Thymic Carcinoma; Mediastinal Tumors; Lung Cancer; Esophageal Cancer; Minimally Invasive Surgery; Pulmonary Metastases; Mesothelioma; Bronchoscopy; Gastrointestinal Endoscopy
New Patient Appointments
Scheduling a visit is easy. Click below or call us to get started.
Dr. Huang accepts the following list of insurance providers. Select your insurance provider to see more details.
Memorial Sloan Kettering is an in-network provider with Aetna HMO, POS, and PPO plans. Aetna does not include us in any of the plans you can purchase through the insurance exchanges or through Medicare. Please ask your insurance if you need a one-time referral. MSK has an agreement with the Aetna Transplant Program for all Aetna's commercial products.
In New York State
Memorial Sloan Kettering is an in-network provider with Empire Blue Cross Blue Shield (Wellpoint) of New York HMO, EPO, PPO, and POS plans, with the following exceptions:
- Empire Blue Cross Blue Shield does not include us in any of the plans you can buy through the insurance exchanges.
- Memorial Sloan Kettering is not an in-network provider for Empire's Medicare Managed Care plan known as Mediblue).
- Memorial Sloan Kettering is a designated Center of Excellence by Blue Cross Blue Shield.
In New Jersey
Memorial Sloan Kettering is an in-network provider with some Horizon Blue Cross Blue Shield of New Jersey plans for individuals, families, and small businesses. For example, the PPO plan is in-network with our Manhattan locations.
Horizon Blue Cross HMO is only in-network with our Basking Ridge, Bergen and Monmouth locations. It does not allow access to our Manhattan facilities.
Horizon Blue Cross PPO is in network with our Basking Ridge, Bergen, Monmouth and Manhattan locations.
OMNIA Plans: Tier I EPO based plan policy is only in-network with our Basking Ridge, Bergen and Monmouth locations and does not allow access to our Manhattan sites. Tier II EPO is only in-network with our Manhattan sites if it is a blue-card plan (there would be a suitcase logo indicating PPO on the front of the card).
Other plans may only be in-network at our Basking Ridge, Bergen or Monmouth locations.
Outside New York State and New Jersey
Some, but not all, Blue Cross Blue Shield plans outside of New York and New Jersey include Memorial Sloan Kettering as an in-network provider. Contact your insurance to find out if your plan provides in-network access to Memorial Sloan Kettering.
We understand that there may be many complexities involved with insurance coverage purchased through the health exchange network of the Affordable Care Act. We’re here to help. If you have questions about how your care will be covered by an insurance provider, or need help navigating a change in coverage, please call us at 646-227-3378; if you are not a resident of New York, you can call us at 866-248-1274. Our team is here to listen to your concerns and assist you in any way we can. We want our care to be as accessible and affordable for as many people as possible.
Memorial Sloan Kettering is an in-network provider with CIGNA's HMO, POS, and PPO plans. CIGNA does not include us in any of the plans you can buy through the insurance exchanges.
- If you are a New York State resident: Please ask your insurance if you need a one-time referral.
- If you live outside of New York State: Please ask your insurance if you have in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with EmblemHealth’s PPO, EPO, POS, HMO plans and Medicare plans. Emblem Health does not include us in any of its Select Care network plans. EmblemHealth includes GHI, HIP, Vytra, and ConnecticCare (in NYS Only). You must bring a referral from your Emblem primary care doctor to your first appointment.
Formerly known as Health Plus Amerigroup, Empire Blue Cross Blue Shield Health Plus is an in-network provider with Memorial Sloan Kettering. You will need a one-time referral from your primary care doctor.
Memorial Sloan Kettering is an in-network provider with HealthFirst’s commercial products; these commercial products are not purchased on the insurance exchanges.
Memorial Sloan Kettering is an in-network provider with HealthSmart’s Accel, HSPC, and HPO networks.
Memorial Sloan Kettering is a designated Center of Excellence by Humana.
Memorial Sloan Kettering is a designated Center of Excellence by Interlink Health Services.
Memorial Sloan Kettering is a designated Center of Excellence by Lifetrac.
Memorial Sloan Kettering is an in-network provider for all MagnaCare health plans except those products you can buy through the insurance exchanges.
Memorial Sloan Kettering is an in-network provider with Medicaid NY Empire Blue Cross Blue Shield HealthPlus (formerly known as Amerigroup). You will need a one-time referral from your primary care doctor.
In New York: Memorial Sloan Kettering’s New York locations are in-network with the Emblem
In New Jersey: Memorial Sloan Kettering’s New Jersey locations in Basking Ridge, Bergen and Monmouth are in-network with the Horizon Medicare Advantage Plan. This plan is not accepted for care provided at MSK’s New York locations.
If you are enrolled in any other Medicare Advantage plan, please contact your insurance carrier to determine your benefits and coverage at Memorial Sloan Kettering since your access may be limited.
Memorial Sloan Kettering is an in-network provider with some Multiplan/Beech Street/PHCS plans. Contact your insurance carrier to find out if your plan provides in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is a designated Center of Excellence by Multiplan.
If you are covered by more than one insurance plan, you will want to determine your benefits from both plans. First, you need to determine which one is your primary insurance provider by contacting your employee benefits office or your insurance carriers. After you find out which is your primary insurance provider, you should then contact your insurance carrier to determine if you have access to Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with some MVP plans. Contact your insurance carrier to find out if your plan provides in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider for New York State employees who have enrolled in UnitedHealthcare's Cancer Resource Services. If you have the Empire Plan, you should call Cancer Resources Services at 866-936-6002 to verify and enroll in this coverage.
Memorial Sloan Kettering is in-network with Oscar’s Circle Plus Network, a part of its Small Group Broad line that is offered only to select small business groups. Oscar does not include Memorial Sloan Kettering as an in-network provider for any of its individual plans. Please confirm eligibility with your insurance carrier.
We have agreements with several insurance companies that may provide additional coverage for cancer patients. These benefit programs include:
- AXA Assistance USA
- Beech Street
- Integrated Health Plans
- National Health Administrators
- National Preferred Provider Network
- UnitedHealthcare's Cancer Resource Services
- United Resource Network
- Veterans Choice Program
Memorial Sloan Kettering is an in-network provider with Oxford’s Freedom and Liberty plans as well as the Metro Plan (which is only offered to small business groups and no longer offered as individual plans). Please confirm with your insurance if you need a one-time referral. Note: Oxford’s Medicare Managed Care plan — Secure Horizon — does not include Memorial Sloan Kettering as an in-network provider. Oxford does not include us in any of the plans you can buy through the insurance exchanges.
Memorial Sloan Kettering is an in-network provider with the World Trade Center Health Program.
Memorial Sloan Kettering is an in-network provider with QualCare's PPO and HMO/POS network.
Memorial Sloan Kettering is a designated Center of Excellence by Specialty Care Management.
Hospital and physician services may be covered by TRICARE. Please call your TRICARE plan to confirm coverage at Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with UnitedHealthCare's HMO, POS, and PPO plans. Please confirm with your insurance if a one-time referral is needed.
UnitedHealthCare's Medicare Managed Care plan does not include Memorial Sloan Kettering as an in-network provider.
United does not include us in any of the plans you can buy through the insurance exchanges.
Memorial Sloan Kettering is a designated Center of Excellence by UnitedHealthcare.
Contact and Location
Memorial Sloan Kettering has locations throughout New York City, Long Island, New Jersey, and Westchester. These locations offers many services, including screening, chemotherapy, and medical testing.
MD, Columbia University
General Surgery - Brigham and Women's Hospital; Cardiothoracic Surgery - Memorial Sloan Kettering Cancer Center
Thoracic Surgery - Memorial Sloan Kettering Cancer Center
Thoracic Surgery; General Surgery
I am a surgeon who specializes in the treatment of cancers of the chest including lung cancer, esophageal cancer, thymoma, thymic carcinoma, mediastinal tumors, lung metastases, and mesothelioma. When possible, I utilize minimally invasive surgical techniques to reduce trauma and speed the recovery process. Video-assisted thoracic surgery (VATS) lobectomy permits the removal of lung tumors through small incisions, and endobronchial ultrasound (EBUS) now provides a much less invasive method to biopsy and stage lung cancer.
I have a special interest in the treatment of patients with thymoma, thymic carcinoma, and other mediastinal tumors. My research centers on increasing our knowledge about these uncommon diseases. By examining the genetic and molecular characteristics of thymomas and thymic carcinomas, we can better understand how these tumors develop and can create new targeted therapies to treat them. To enhance the quality of our care, I developed and maintain the Memorial Sloan Kettering thymoma database to follow the outcomes of our patients. My colleagues and I are actively pursuing clinical trials to find more-effective therapies to treat these tumors. The treatment of these tumors often requires a collaborative effort between surgeons, oncologists and radiation oncologists, and we are fortunate here at Memorial Sloan Kettering to have a team of experts specifically interested in thymoma and thymic carcinoma.
In addition, I am also committed to the training of future leaders in thoracic surgery. I lead the teaching program for our fellows in thoracic surgery and serve on a national committee overseeing all thoracic surgery training programs in the United States. The interaction we have with our fellows and students is a continual source of renewal and enrichment. Educating the physicians of tomorrow is a unique privilege that will continue to advance our fight against cancer.
Awards and Honors
- Castle Connolly: New York Magazine Top Doctors (2016, 2018-2020)
Doctors at Memorial Sloan Kettering work as teams, with specialists from all different areas. This allows us to consider all your needs together, and to give you the best possible care.
- Clinical Trials Co-Investigated by Dr. Huang
- A Phase II Study of Local Consolidation Therapy after Osimertinib Compared with Osimertinib Alone in People with Metastatic Non-Small Cell Lung Cancer
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Research and Publications
Selected Book Chapters
“Multidisciplinary management of thymic carcinoma.” Riely G, Huang J, Rimner A. ASCO 2012 Educational Book. Alexandria, Virginia: American Society of Clinical Oncology; 2012.
“Unusual primary malignant neoplasms of the lung.” Bott MJ, Huang J. In: Current Therapy in Thoracic and Cardiovascular Surgery. 2nd ed. Yang SC, Cameron DE, eds. London, UK: Elsevier. (In press)
Articles in Journals
Yu HA, Sima CS, Huang J, Solomon SB, Rimner A, Paik P, Pietanza MC, Azzoli CG, Rizvi NA, Krug LM, Miller VA, Kris MG, Riely GJ. Local therapy with continued EGFR tyrosine kinase inhibitor therapy as a treatment strategy in EGFR-mutant advanced lung cancers that have developed acquired resistance to EGFR tyrosine kinase inhibitors. J Thorac Oncol. 2013 Mar;8(3):346-51.
Sarkaria IS, Rizk NP, Finley DJ, Bains MS, Adusumilli PS, Huang J, Rusch VW. Combined thoracoscopic and laparoscopic robotic-assisted minimally invasive esophagectomy using a four-arm platform: experience, technique and cautions during early procedure development. Eur J Cardiothorac Surg. 2013 Jan 30.
Lou F, Huang J, Sima CS, Dycoco J, Rusch V, Bach PB. Patterns of recurrence and second primary lung cancer in early-stage lung cancer survivors followed with routing computed tomography surveillance. J Thorac Cardiovasc Surg. 2013 Jan;145(1):75-81; discussion 81-2. Epub 2012 Nov 3.
Wagner PL, McAleer E, Stillwell E, Bott M, Rusch VW, Schaffer W, Huang J. Pericardial effusions in the cancer population: prognostic factors after pericardial window and the impact of paradoxical hemodynamic instability. J Thorac Cardiovasc Surg. 2011 Jan;141(1):34-8.
Huang J, Rizk NP, Travis WD, Riely GJ, Park BJ, Bains MS, Dycoco J, Flores RM, Downey RJ, Rusch VW. Comparison of patterns of relapse in thymic carcinoma and thymoma. J Thorac Cardiovasc Surg. 2009 Jul;138(1):26-31.
Huang, J., Lin, S., Nadershahi, A., Watts, S., Sarkar, R. Role of redox signaling and poly (adenosine diphosphate-ribose) polymerase activation in vascular smooth muscle cell growth inhibition by nitric oxide and peroxynitrite. Journal of Vascular Surgery. 47(3):599-607, 2008 Mar.
Huang, J., Rizk, NP., Travis, WD., Seshan, VE., Bains, MS., Dycoco, J., Downey, RJ., Flores, RM., Park, BJ., Rusch, VW. Feasibility of multimodality therapy including extended resections in Stage IVA thymoma. Journal of Thoracic and Cardiovascular Surgery. 134(6):1477-83, 2007 Dec.
Huang, J., Rizk, N., Park, B., Bains, M., Flores, R., Downey, R., Rusch, V. Recent clinical experience with multimodality therapy in thymic carcinoma. Journal of Clinical Oncology (Meeting Abstracts) 2007; 25: 18003
Puhlmann M., Brown CK., Gnant M., Huang J., Libutti SK., Alexander HR., Bartlett DL. Vaccinia as a vector for tumor-directed gene therapy: biodistribution of a thymidine kinase-deleted mutant. Cancer Gene Therapy. 7(1): 66-73, 2000 Jan.
Gnant MF., Berger AC., Huang J., Puhlmann M., Wu PC., Merino MJ., Bartlett DL., Alexander HR., Libutti SK. Sensitization of tumor necrosis factor alpha-resistant human melanoma by tumor-specific in vivo transfer of the gene encoding endothelial monocyte-activating polypeptide II using recombinant vaccina virus. Cancer Research. 59(18): 4668-74, 1999 Sep 15.
Wu P., Alexander HR., Huang J., Hwu P., Gnant M., Berger AC., Tuner E., Wilson O., Libutti SK. In vivo sensitivity of human melanoma to tumor necrosis factor (TNF)-alpha is determined by tumor production of the novel cytokine endothelial monocyte-activating polypeptide II (EMAP II). Cancer Research. 59(1): 205-12, 1999 Jan 1.
Wu, P., Berger, A., Huang, J., Gnant, M., Turner, E., Alexander, H., Libutti, S. In vivo tumors that overexpress endothelial monocyte-activating polypeptide II demonstrate upregulation of tumor necrosis factor receptor p55 on tumor neovasculature. Surgical Forum, 49: 436-438, 1998.
Park B., Alexander HR., Libutti SK., Huang J., Royalty D., Skarulis MC., Jensen RT., Gorden P., Doppman JL., Shawker T., Fraker DL., Norton JA., Bartlett DL. Operative management of islet-cell tumors arising in the head of the pancreas. Surgery. 124(6): 1056-61; discussion 1061-2, 1998 Dec.
Allendorf JD., Bessler M., Huang J., Kayton ML., Laird D., Nowygrod R., Treat MR. Helium-neon laser irradiation at fluences of 1, 2, and 4 J/cm2 failed to accelerate wound healing as assessed by both wound contracture rate and tensile strength. Lasers in Surgery and Medicine. 20(3): 340-5, 1997.
Yan SF., Tritto I., Pinsky D., Liao H., Huang J., Fuller G., Brett J., May L., Stern D. Induction of interleukin-6 (IL-6) by hypoxia in vascular cells. Central role of the binding site for nuclear factor-IL-6. Journal of Biological Chemistry. 270(19): 11463-71, 1995 May 12.
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
James Huang discloses the following relationships and financial interests:
No disclosures meeting criteria for time period
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2019 through disclosure submission in spring 2020). This data reflects interests that may or may not still exist. This data is updated annually.